Company intelligence / Profile preview

Theravia

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Theravia has successfully launched several life-saving medications for rare diseases, including SIKLOS for sickle cell disease and ORPHACOL for genetic disorders affecting liver bile production.

Therapeutic areas: Rare DiseasesHematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

SIKLOS

Commercial

Indications: Sickle cell disease

1 more asset in the full pipeline.

Request access →

Partnerships

Over 30 partnerships mentioned but not specifically named

Beyond the preview

Go deeper on Theravia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theravia.

Explore the full profile